Formulation, Optimization and Evaluation of Rimegepant Pulsatile Tablets for Chronotherapeutic Management of Migraine
Background: Migraine attacks frequently show circadian variation, and conventional immediate-release oral dosage forms may not provide drug exposure at the most therapeutically relevant time. Rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, is an effective agent for acute and preventive migrain...